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Heart Failure (HF) is a common syndrome with multiple causes. Cardiovascular magnetic resonance (CMR) is a medical imaging
technique with signiﬁcant advantages, allowing the understanding of aetiology and pathophysiology of HF in the individual
patient, permitting speciﬁc therapy to be administered and predicting prognosis. This paper discusses the diverse role of CMR
in HF.
1.Introduction
Heart failure (HF) is a syndrome arising from any cardiac
disease severe enough to impair the heart’s ability to support
the physiological circulation. Clinically, it is characterised
by a number of symptoms and signs most of which relate
to ﬂuid accumulation; particularly fatigue, breathlessness,
cough, and peripheral oedema. The incidence and mortality
of HF is high with more than 24,000 deaths a year in the
UK [1] and a 30% mortality within 1 year of ﬁrst hospital
admission [2]. In the United States, 1 in 8.6 death certiﬁcates
(282,754 deaths/year) mention HF [3]. Management of HF
involves prevention, diagnosis of the underlying aetiology,
treatment of symptoms, and prevention of disease progres-
sion. This may include drug therapy aimed at maladaptive
processes within the pathophysiology of heart failure—
typically blockade of the renin-angiotensin system, drugs for
symptoms (for example diuretics) and nonpharmacological
treatment (particularly exercise and dietary changes). Device
therapy may also be appropriate (ICD, biventricular pace-
maker, ventricular assist devices) and at end stage, cardiac
transplantation may be considered. Speciﬁc therapy tailored
to the etiology of HF is also available. Common causes
of HF are coronary artery disease (mainly infarction but
withsomeroleformyocardialischaemia),hypertensiveheart
disease, valvular heart disease, diabetes, myocarditis, car-
diomyopathies, tachycardia-induced cardiomyopathy, and
systemic diseases with cardiac manifestations. Within an
individual, often more than one etiology is present. Com-
mon contributory factors exacerbating symptoms within
individuals may include lung disease, obesity, detraining,
andsimultaneousdiseaseinvirtuallyanyotherorgansystem.
The approach to the HF work-up is systematised. Di-
agnosis of the syndrome is based on history, clinical exam-
ination, electrocardiography, chest radiograph, and blood
tests (including BNP and tests for heart failure mimics—
hypoalbuminaemia, hypothyroidism, and anaemia). Imag-
ing in HF is challenging and requires a multimodality
approach. Echocardiography is the ﬁrst-line investigation for
assessment of cardiac anatomy, function, and dynamics. It
is cheap, widely available and can be done at the bedside.
However, it is limited by poor image quality in some patients
and gives very little information about tissue characteristics
and coronary anatomy. Cardiovascular magnetic resonance
(CMR) provides additional incremental data in patients with
HF, providing accurate quantiﬁcation of systolic dysfunc-
tion, determining aetiology and prognosis and predicting
response to and selecting therapy. The excellent image
quality obtained by CMR allows a detailed examination
of cardiac structure and function, without the need for
ionising radiation. There are also the key advantages of
tissue characterisation (unique to CMR) and perfusion
imaging. Evaluation of HF is therefore one of the major
current roles of CMR in clinical medicine with the pilot
EuroCMR registry of 11,000 patients ﬁnding that the most
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potential myocarditis/cardiomyopathy [4]. In this registry,
CMR impacted on the management of two thirds of patients
and in 16% a new cardiac diagnosis was made that had not
been apparent previously.
Assessmentofthecoronaryarteriesiscurrentlylimitedto
assessment of origins and proximal courses using CMR. The
small calibre of the vessels and movement during the cardiac
cycle make ﬂow limiting disease diﬃcult to evaluate using
this modality [5]. Cardiac CT or percutaneous angiography
are therefore required for anatomical assessment of nearly all
patients with potential coronary disease.
This paper provides an overview of the principles of
CMR and then discusses its role in speciﬁc conditions that
can cause HF.
2. The CMR Process
CMR is the use of MRI to image the heart. Any modern
MRI scanner can be used, once ECG gating and speciﬁc
sequences for cardiac work are installed. Scans are typically
performed during multiple 7–15 second breath holds, with
standardized protocols according to the referral indication
[6, 7] .T h eﬁ r s t1 0m i n u t e so faC M Rs t u d yi sa l w a y s
to assess anatomy and cardiac structure and function—
a volume and function study. This typically uses double-
oblique imaging orientated to the long and short axes of the
heart using steady-state free precession (SSFP) ECG gated
cine imaging. The result is a highly reproducible, stereotyped
set of images which are acquired in the same way in all CMR
centres [8]. At the end of almost any CMR study is late
gadolinium enhancement imaging (LGE, see below) looking
for myocardial scar from infarction, cardiomyopathy, or
myocarditis. In between, additional techniques may be used,
including myocardial blood velocities/ﬂow (e.g., for detect-
ing shunts, valve disease), cardiac iron quantiﬁcation (iron
overload), oedema imaging (acute myocarditis, sarcoidosis,
infarction), T1-weighted imaging (pericardial disease and
masses), tagging (pericardial disease, diastology), real-time
imaging during respiration (diaphragm paralysis, pericardial
constriction), stress imaging (vasodilator or inotropic stress
for ischaemia/hibernation), tumour tissue characterisation,
and early postcontrast imaging (thrombus, microvascular
obstruction). A typical HF protocol would take 40 minutes.
For further details, see Table 1.
3. GadoliniumEnhancement Imaging
CMR is excellent for distinguishing diﬀerent soft tissues
based on their magnetic properties described by the relax-
ations times T1, T2, and T2∗. Normal and abnormal
myocardium may have diﬀerent relaxation times, but the
addition of a gadolinium contrast agent greatly magniﬁes
these diﬀerences. Gadolinium is chelated and behaves as a
passive, extravascular, extracellular contrast agent. After an
intravenous bolus, three time phases are considered. The
ﬁrst pass can be used for perfusion imaging and is often
given during vasodilator stress to detect ischaemia. Early
aftercontrast,severelyhypovascularregionswillnotenhance
(thrombus or microvascular obstruction in acute myocardial
infarction). In the late phase (5 minutes plus post bolus),
contrast lingers in areas of infarction or focal ﬁbrosis due to
slower contrast kinetics and a greater volume of distribution
in extracellular water associated with collagen. When imaged
using a sensitive sequence (inversion recovery), focal ﬁbrosis
appears bright—a region of late gadolinium enhancement
(LGE). This can be assessed either visually or quantitatively
based on relative enhancement compared to the background
[9]. The extent and pattern of LGE varies according to the
underlying disease process and is frequently of prognostic
signiﬁcance and can be diagnostic of the underlying etiology.
4.CMRSafety
Sternal wires and all cardiac prosthetic valves and car-
diac stents in use in the UK are CMR safe at 1.5 and
3T. Many intravascular clips are not safe. All ICDs and
most pacemakers are not safe with the risk of malfunction
andsigniﬁcantheatingofthepacemakerleads.Therearenow
CMRconditionalpacemakers(generatorandleads)available
(Figure 1). In the vast majority of patients, gadolinium con-
trast agents are safe—safer than iodine-based contrast. How-
ever, in patients with an estimated glomerular ﬁltration rate
of<30mL/min,onlycyclicgadolinium-basedcontrastagents
should be used, and then only after risk-beneﬁt analysis and
at the minimum dose because of the possibility of the severe
condition, nephrogenic systemic ﬁbrosis (NSF) [10].
5. PracticalClinicalIssues
T h em o s tc o m m o nr e a s o nf o rt h ef a i l u r et oc o m p l e t eaC M R
examination is claustrophobia. In one study, this resulted in
4.2% of patients refusing to undergo CMR [11]. However,
with scanning patients feet ﬁrst, prone, the occasional use
of low dose oral (or intra venous) sedation and sensitive
treatment, nearly all patients who arrive in a department can
be successfully scanned. Some patients with HF may be dif-
ﬁcult to scan—either due to inability to lie ﬂat, poor breath
holding, or atrial ﬁbrillation with uncontrolled ventricular
rates. Real-time, ungated cine imaging, parallel imaging,
highly eﬃcient sequence, arrhythmia rejection sequences,
and single shot late enhancement sequences help overcome
some of these diﬃculties. On occasions, scanning may be
deferred or repeated when patients clinically improve,par
ticularly if the patient is not be able to lie ﬂat due to an acute
decompensation of their HF.
6. CMR inMyocardialInfarction
6.1. Acute Myocardial Infarction. CMR can be safely carried
out in patients following acute infarction and primary
angioplasty and aids risk stratiﬁcation [12–15]. T2-weighted
imaging detects myocardial oedema, allows for early diag-
nosis of myocardial ischaemia, area at risk and salvage [16],
and may diﬀerentiate between acute and chronic infarction.
T2∗ changes occur in intramyocardial haemorrhage in
acute infarction, an adverse prognostic marker [17–20].Cardiology Research and Practice 3
(a) (b)
(c) (d)
Figure 1: A CMR conditional pacemaker. (a, b) show the pacemaker on a chest X-ray. On (b) the arrows point to MRI conditional markers
on the header and leads. (c) shows a large artifact from the pacemaker box on a transverse white blood stack. (d) shows suseptibility artifact
from the pacemaker leads in the heart.
(a) (b)
Figure 2: CMR in a patient with ischaemic cardiomyopathy. The cine imaging had shown normal wall thickness throughout but septal
akinesis. (a) First pass perfusion sequence following administration of vasodilator stress with adenosine. A defect is seen throughout the
septum. (b) Almost full thickness LGE is seen in the septum highly suggestive that this area is nonviable.4 Cardiology Research and Practice
Table 1: Sequences commonly employed during a CMR examination.
Sequence When commonly used Information obtained
Localisers All studies Allows cardiac piloting of all future images. Also
allows extra cardiac structures to be assessed
Transverse Thoracic Stack All studies Assessment of extra cardiac thoracic structures
Cardiac long axis and LV short axis cines All studies Assessment of LV and RV volumes, systolic
function and regional wall motion abnormality
Flow Valve Disease/Shunts
Quantiﬁcation of Qp:Qs shunt ratio.
Quantiﬁcation of valve regurgitant fraction and
forward ﬂow velocity.
T1 weighted turbo spin echo ARVC assessment Demonstration of myocardial fat
STIR Acute Myocardial Infarction and
Myocarditis Demonstration of myocardial oedema
T2∗ Iron overload syndromes (e.g., Beta
Thalassaemia major)
Demonstration and quantiﬁcation of myocardial
and liver iron
Gadolinium First Pass Perfusion
(with and without vasodilator stress)
Ischaemic Heart Disease, Cardiac mass
assessment
Demonstration of perfusion defects in areas of
ischaemic myocardium. Assessment of the
vascularity of a cardiac mass
Gadolinium Enhanced Aortogram Aortic Disease Demonstration of dissection/dilatation of the
aorta.
Early Gadolinium Inversion Recovery Assessment of intracardiac mass Demonstration of LV or left atrial appendage
thrombus
Late Gadolinium Inversion Recovery Nearly All Studies
Assessment of LV infarction and viability in
ischaemic heart disease. Assessment of ﬁbrosis in
Cardiomyopathies.
(a) (b)
(c) (d)
Figure 3: CMR cine sequences demonstrating the diﬀering morphologies of inherited cardiomyopathies. (a) HCM: asymmetric basal
anterospetal wall hypertrophy; (b) LVNC: left ventricular hypertrabeculation and dilatation; (c) FDCM: left ventricular wall thinning and
dilatation; (d) ARVC: right ventricular dilatation.Cardiology Research and Practice 5
(a) (b)
(c) (d)
Figure 4: Tissue characterisation in inherited cardiomyopathy. (a) Patchy anteroseptal wall LGE in HCM; (b) Basal inferolateral wall LGE in
Anderson Fabry Disease; (c) Septal and anterior mid wall LGE in familial FDCM; (d) RV fatty replacement in ARVC on the trabeculae and
possibly the free wall.
Microvascular obstruction, the tissue equivalent of the no-
reﬂow phenomenon, can be easily detected by CMR. It is
associated with adverse ventricular remodelling and clinical
outcome[21,22].Withinareasofmicrovascularobstruction,
myocardial haemorrhage may occur which carries an incre-
mental adverse prognosis [23].
Following the onset of coronary occlusion, irreversible
myocardialinjury/myocytenecrosisdevelopsasatransmural
wavefront which begins in the subendocardium and moves
progressively towards the epicardium [24]. LGE CMR can
detect even small volumes of focal injury (in the order
of grams) and identiﬁes subendocardial scar not otherwise
captured by regional contractile function or SPECT imaging
[25]. The volume of LGE in acute infarction has been shown
tobeastrongindependentpredictorofbothheartfailureand
poor outcomes [26].
The excellent spatial resolution and wide ﬁeld of view in
CMR also allows for identiﬁcation of the complications of
acute infarction including thrombus, true or false aneurysm,
papillary muscle involvement, and ventricular septal defect.
6.2. Chronic Myocardial Infarction (Figure 2). The use of
CMR in chronic myocardial infarction helps to guide ther-
apeutic and revascularisation decisions. As well as looking
at rest perfusion images, imaging can be performed during
vasodilatorstresstoderiveﬂowreserve.Perfusiondefectscan
therefore be observed and the cause of these can be clariﬁed
by comparing the LGE images and regional wall motion
abnormalities on cine imaging. Low dose dobutamine stress
CMR can also be used to assess myocardial contractile
reserve.
Leftventriculardysfunctionsecondarytocoronaryartery
disease typically is either reversible as in states of ischaemia,
or potentially irreversible, as in transmural myocardial in-
farction. As ischaemic cardiomyopathy is potentially re-
versible, the assessment of myocardial viability is extremely
valuable. CMR can assess multiple markers of myocardial
viability in a single examination [27].
Myocardial infarction has a characteristic LGE pattern
due to the wavefront of myocardial necrosis. This always
involves the subendocardium at the core of the infarct,
although it may be transmural. Transmurality predicts po-
tential functional recovery but with a grey-zone of 50%
transmural infarction recovery with revascularisation it is
more diﬃcult to predict [28]. Low dose dobutamine can
provide incremental information.
The identiﬁcation of viable (dark on late gadolin-
ium imaging) myocardium in a patient with regional or
global left ventricular systolic dysfunction in the setting of
ischaemic heart disease can represent hibernation, stunning,
dilated cardiomyopathy, or dyssynchrony [28–30]. Such6 Cardiology Research and Practice
(a) (b)
Figure 5: A patient with known apical HCM in whom transthoracic echocardiography had suggested a secundum ASD. (a) Cine 4 chamber
image showing apical hypertrophy (b) ﬂow sequence planned using the 4 chamber view shows ﬂow across the intra atrial septum from left
to right (arrowed), conﬁrming the diagnosis. In this case, although the right heart does not appear dilated, the Qp:Qs was calculated as 2
showing the presence of a signiﬁcant shunt.
myocardium may recover functionally with time (stunning),
revascularisation (hibernation), or resynchronisation (see
below). In addition, medical therapy (beta-blockers in par-
ticular) are more likely to improve cardiac function in
the presence of living but dysfunctional myocardium.
7. CMR inInheritedCardiomyopathy
(Figures3 and4)
7.1. Hypertrophic Cardiomyopathy (HCM). This autosomal
dominant disease resulting in otherwise unexplained left
ventricular hypertrophy can present with a number of
diﬀerent clinical phenotypes and in some patients will result
in the development of HF and sudden death [31]. CMR
is an important investigation in its work-up. High reso-
lution cine images allow accurate hypertrophy assessment,
particularly useful in apical hypertrophy which is diﬃcult
to visualise using echocardiography [32]. Complex left or
right ventricular outﬂow tract obstruction is well visualised
to plan intervention. First pass gadolinium imaging can
show perfusion defects whilst LGE sequences show the
quantity and distribution of ﬁbrosis, which predicts future
HF [33]. In contrast to ischaemic cardiomyopathy, the late
enhancement pattern will not follow a coronary distribution
and rarely involves the subendocardium. CMR can also
identify phenocopies (or genocopies) of HCM, with char-
acteristic ﬁndings in Anderson Fabry disease (such as basal
inferolateral mid wall late enhancement) and amyloidosis
(diﬀerent gadolinium kinetics with global subendocardial
enhancement), both of which may have speciﬁc therapeutic
options [34].
7.2. Familial Dilated Cardiomyopathy (FDCM). FDCM is
characterised by left ventricular (LV) dilatation and impair-
ment on the background of a family history [35]. CMR
provides the accurate assessment of LV and right ventricular
(RV) volumes, mass, and systolic function. Around 35% of
patients with FDCM will have mid myocardial wall LGE,
with some evidence that this is a risk factor for sudden
cardiac death and ventricular arrhythmia [36]. The pattern
of LGE can sometimes be useful in suggesting the underlying
genetic basis of FDCM, with dystrophinopathies often show-
ing enhancement of the basal inferolateral segment [37]. It
can also help to rule out phenocopies of FDCM, particularly
ischaemic cardiomyopathy in older patients.
7.3. Arrhythmogenic Right Ventricular Cardiomyopathy
(ARVC). This disease is characterised by ﬁbrofatty
inﬁltration of the right or both ventricles [38]. It may
present with sudden cardiac death, although in latter stages
can cause biventricular systolic impairment and hence HF.
It is a challenging disease to diagnose as assessment of the
RV by echocardiography is diﬃcult and limited due to its
complex and variable geometry. The multiple image planes
that can be performed during CMR make RV assessment
less unreliable. Recently published international task force
guidelines emphasise assessment of regional wall motion
abnormality and RV volumes and ejection fraction [39].
Although not mentioned in the task force criteria, CMR
can also be used to identify areas of myocardial ﬁbrofatty
inﬁltration [40].
7.4. Left Ventricular Noncompaction (LVNC). This disease
is characterised by the presence of a thick endocardium
with prominent trabeculation and deep recesses commu-
nicating with the LV cavity [41]. In some cases it can
result in HF via LV systolic impairment. Noncontrast-
enhanced echocardiography is limited in the evaluation of
LVNC as the LV apex is often poorly visualised. Cine CMRCardiology Research and Practice 7
(a) (b)
(c) (d)
Figure 6: Gadolinium-enhanced imaging in speciﬁc cardiac diseases. (a) Subendocardial LGE in a patient with AL amyloidosis. (b) Mid
anterior wall focal LGE lesions in a patient with sarcoidosis. (c) Epicardial and mid wall anterior LGE in a patient with myocarditis. (d)
Subendocardial enhancement in a patient with Churgg Strauss syndrome.
imaging will provide excellent views of the LV apical endo-
cardium, with early and late gadolinium contrast imaging
allowing evaluation for thrombus. However at present LVNC
is a complicated and often debateable diagnosis particularly
due to wide normal variation and there is no consensus on
diagnostic criteria [42].
8.CMR inIntracardiacShunting(Figure5)
andOther Congenital Heart Disease
Heart failure is the ﬁnal common pathway for many types
of congenital heart disease. CMR can assist in the morpho-
logical diagnosis, functional assessment, angiography, ﬂow
and tissue characterisation, monitoring ventricular function,
and tracking change over time. Flow analysis allows shunt
detection—a ratio of >1.5 is considered signiﬁcant and likely
to result in patient symptoms (including those of heart
failure) at some stage [43]. Cine imaging can then be used
to demonstrate the shunt anatomy including ASDs, VSDs,
anomalous pulmonary venous drainage, and more complex
disease [44]. CMR is the gold standard for investigating
complex disease, and its use has dramatically reduced the
need for invasive angiographic assessment [45]. Its primary
limitation is that direct measurement of pressures cannot
be made and so pulmonary vascular resistance cannot be
directly assessed.
9. CMR inPericardialDisease
Pericardial disease, particularly pericardial restriction can
cause HF in the presence of preserved ejection fraction
but impairing cardiac ﬁlling [46]. CMR can detect the
anatomy of pericardial thickening; the local and systemic
functional consequences (e.g., tethering of the pericardium
to myocardium, eﬀusions), and the nonquantitative haemo-
dynamics of pericardial constriction with ventricular: ven-
tricularinteractioneitheratrestoronreal-timecineimaging
during inspiration (where preferential ﬁlling of one ventricle
due to respiration restricts the other, with a clear septal
deviation associated) [47–49]. The assessment of pericardial
calciﬁcation is better performed using CT scanning.
10. CMR inValvular HeartDisease
Echocardiography is the ﬁrst-line test for valvular heart
disease, providing excellent assessment of haemodynamics
and anatomy in most patients. CMR has incremental value,
particularly where echocardiographic windows are poor
[50].
Cine imaging will allow precise evaluation of ventricular
size and function which can be important in deciding when
to surgically intervene in valvular disease [51]. It will also
provide high-quality imaging of the valve anatomy allowing8 Cardiology Research and Practice
accurate planimetry of the aortic valve to be performed. In
aortic valve disease, cine imaging and gadolinium enhanced
aortography will show the anatomy of the aorta in three
dimensions. CMR is also very useful for assessment of
pulmonary valve disease which can be diﬃcult with echocar-
diography.
Flow sequences will allow the calculation of the regurgi-
tantfractioninregurgitantvalvediseaseandtheforwardﬂow
maximal velocity in stenotic disease [52, 53].
11. CMRinSpeciﬁcAcquiredCardiomyopathies
(Figure6)
11.1. Sarcoidosis. In the thorax, sarcoidosis usually manifests
with disease in the lungs, lymph nodes, or heart. Autopsy
evidencehasshownthatcardiacinvolvementcanoccurinup
to 30% of cases [54]. CMR assessment can show extracardiac
disease. If cardiac involvement is present, T2-weighted se-
quences can highlight areas of acute inﬂammation. LGE
sequences will show enhancement in areas of disease, which
is usually multifocal and in the mid or subepicardial layers
[55].Inpatientswhorequireendomyocardialbiopsytomake
thediagnosis,thereissomeevidencethattargetingareaswith
LGE increases the diagnostic yield of the procedure [56].
11.2. Myocarditis. This condition is caused by inﬂammation
of the myocardium, most commonly as result of infection
[57]. It can progress and result in a dilated cardiomyopathy
and hence HF [58]. T2-weighted CMR sequences will
show areas of acute inﬂammation. LGE will identify areas
of necrosis or severe oedema. This is most commonly
seen in the septal or basal inferolateral wall in the mid
orsubepicardiallayers[59].Myocarditisisacommonﬁnding
on CMR in patients presenting with chest pain and an
ECG/biomarkers suggesting myocardial infarction, but a
normal coronary angiogram. One recent study found that
60% of patients presenting in this manner had myocarditis
[60]. Such patients may not have any regional wall motion
abnormality and so tissue characterisation using CMR is the
only noninvasive method for making the diagnosis.
11.3. Iron Overload. The most common cause of iron over-
load cardiomyopathy is repeated blood transfusions in
patients with beta thalassemia major. This results in a 50%
mortality in patients under the age of 35 years [61]. CMR
allows the accurate quantiﬁcation of cardiac iron levels using
theT2starmethod[17].Thisallowsidentiﬁcationofpatients
who are at risk of developing HF, allowing more aggressive
iron chelation therapy to be administered.
11.4. Cardiac Amyloidosis. Cardiac involvement is common
in patients with AL or TTR amyloidosis. The presence of
amyloid protein results in accelerated removal of gadolinium
from the blood and increased myocardial uptake, such that
more of it is present in the myocardium than the blood pool
[62]. This change in gadolinium kinetic behaviour is almost
unique to amyloidosis. The LGE pattern in amyloidosis is
often subendocardial and seen in a circular pattern through-
out the LV. This is in keeping with histological evidence
demonstrating where cardiac amyloid deposition occurs
[63].
11.5. Eosinophilic Diseases. Cardiac hypereosinophilia (e.g.,
malignant, Loeﬄers; Churgg-Strauss) causes endomyocar-
dial ﬁbrosis, valve disease and papillary muscle dysfunction,
diastolic dysfunction, intracardiac thrombus formation, and
heart failure. These are highly characteristic and well diag-
nosed and followed by CMR using T2-weighted imaging,
early and late gadolinium techniques [64, 65].
11.6. Chagas Disease. Endemic in South America, the chron-
ic phase may result in heart failure [66]c h a r a c t e r i s e db y
myocardial ﬁbrosis, sometimes mimicking infarction. CMR
LGEiscommonandtheextentofLGEcorrelateswithdisease
severity [67].
12.CMR andBiventricularPacing
Cardiacresynchronisationtherapy(CRT)usingbiventricular
pacing is a commonly used treatment for patients with HF
and limiting symptom [68]. Upto 1/3 of patients fail to
respond despite stratiﬁcation by the ECG QRS duration.
Results using echocardiographic markers of dyssynchrony
have been mixed [69]. CMR cine and tagging sequences
are being investigated [70], but one promising marker is
ventricularscarburdenanddistribution.Ahighscarburden,
predicts nonresponse, and even more robustly, posterior scar
(the location of the LV lead) virtually precludes response
[71]. It may also be possible by CMR to determine coronary
sinusLVbranchanatomytotargettheLVleadawayfromscar
areas [72].
13. Conclusions
The incidence of HF remains high throughout the world.
CMR using the methods described above, is establishing
itself as the gold standard non invasive method for phe-
notyping this condition, providing important insight into
both the aetiology and pathophysiology of this syndrome
in individual patients. In future years we expect that CMR
will provide us with continuing improvements in image
quality. Many new sequences are likely to become available
which for example will improve LGE imaging [73] and allow
assessment of diﬀuse myocardial ﬁbrosis [74] ;av a r i a b l e
that at present can only be assessed by invasive biopsy.
Most importantly, we envisage CMR becoming more widely
available, allowing a greater number of patients with HF to
undergo this important investigation.
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